Anti-inflammatory action of arachidonoyl lysophosphatidylcholine or 15-hydroperoxy derivative in zymosan A-induced peritonitis

Prostaglandins and Other Lipid Mediators

Volumn 90, Issue 3-4, 2009, Pages 105-111

  Hung, Nguyen Dang ^a   Kim, Mee Ree ^a   Sok, Dai Eun ^a  

^a Chungnam National University   (South Korea)

Author keywords

15 HPETE lysoPC; Anti inflammatoryarachidonoyl lysoPC; Lipoxin A4; LTC4; Zymosan A

Indexed keywords

15 HYDROPEROXY DERIVATIVE; ARACHIDONOYL LYSOPHOSPHATIDYLCHOLINE; CHOLINE DERIVATIVE; UNCLASSIFIED DRUG; ZYMOSAN;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HYDROLYSIS; MALE; MOUSE; NONHUMAN; OXIDATION; PERITONITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; DINOPROSTONE; LEUKOTRIENE C4; LEUKOTRIENES; LIPID PEROXIDES; LIPOXINS; LIPOXYGENASE INHIBITORS; LYSOPHOSPHATIDYLCHOLINES; MALE; MICE; MICE, INBRED ICR; PERITONEAL LAVAGE; PERITONITIS;

EID: 71549165116     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2009.10.001     Document Type: Article

References (47)

1. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 6 (2005) 1191-1197
2. Farooqui A.A., Horrocks L.A., and Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 101 (2007) 577-599
3. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294 (2001) 1871-1875
4. Schwab J.M., and Serhan C.N. Lipoxins and new lipid mediators in the resolution of inflammation. Curr Opin Pharmacol 6 (2006) 414-420
5. Kühn H., and O'Donnell V.B. Inflammation and immune regulation by 12/15-lipoxygenases. Prog Lipid Res 45 (2006) 334-356
6. Daleau P., and Lysophosphatidylcholine. a metabolite which accumulates early in myocardium during ischemia, reduces gap junctional coupling in cardiac cells. J Mol Cell Cardiol 31 (1999) 1391-1401
7. Fuchs B., Schiller J., Wagner U., Häntzschel H., and Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem 38 (2005) 925-933
8. Muralikrishna Adibhatla R., and Hatcher J.F. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40 (2006) 376-387
9. Shi Y., Zhang P., Zhang L., et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 191 (2007) 54-62
10. Fuentes L., Hernández M., Fernández-Avilés F.J., Crespo M.S., and Nieto M.L. Cooperation between secretory phospholipase A2 and TNF-receptor superfamily signaling: implications for the inflammatory response in atherogenesis. Circ Res 91 (2002) 681-688
11. Cunningham T.J., Yao L., and Lucena A. Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties. J Inflamm (Lond) 22 (2008) 17
12. Colles S.M., and Chisolm G.M. Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J Lipid Res 41 (2000) 1188-1198
13. Matsubara M., Hasegawa K., and Benidipine. a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis 178 (2005) 57-66
14. Takeshita S., Inoue N., Gao D., et al. Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase. J Atheroscler Thromb 7 (2000) 238-246
15. Silliman C.C., Elzi D.J., Ambruso D.R., et al. Lysophosphatidylcholines prime the NADPH oxidase and stimulate multiple neutrophil functions through changes in cytosolic calcium. J Leukoc Biol 73 (2003) 511-524
16. Park C.H., Kim M.R., Han J.M., and Sok D.E. Lysophosphatidylcholine exhibits a selective cytotoxicity, accompanied by ROS formation, in RAW 264.7 macrophages. Lipids 44 5 (2009) 425-435
17. Huang L.S., Kim M.R., and Sok D.E. Linoleoyl lysophosphatidylcholine is an efficient substrate for soybean lipoxygenase-1. Arch Biochem Biophys 455 (2006) 119-126
18. Huang L.S., Kim M.R., and Sok D.E. Oxygenation of 1-docosahexaenoyl lysophosphatidylcholine by lipoxygenases; conjugated hydroperoxydiene and dihydroxytriene derivatives. Lipids 42 (2007) 981-990
19. Huang L.S., Kang J.S., Kim M.R., and Sok D.E. Oxygenation of arachidonoyl lysophospholipids by lipoxygenases from soybean, porcine leukocyte, or rabbit reticulocyte. J Agric Food Chem 56 (2008) 1224-1232
20. Okita M., Gaudette D.C., Mills G.B., and Holub B.J. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer 71 (1997) 31-34
21. Croset M., Brossard N., Polette A., and Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 345 (2000) 61-67
22. Adachi J., Asano M., Yoshioka N., Nushida H., and Ueno Y. Analysis of phosphatidylcholine oxidation products in human plasma using quadrupole time-of-flight mass spectrometry. Kobe J Med Sci 52 (2006) 127-140
23. Huang L.S., Kim M.R., and Sok D.E. Regulation of lipoxygenase activity by polyunsaturated lysophosphatidylcholines or their oxygenation derivatives. J Agric Food Chem 56 (2008) 7808-7814
24. 2. Prostaglandins 30 (1985) 769-789
25. Rao T.S., Currie J.L., Shaffer A.F., and Isakson P.C. In vivo characterization of zymosan-induced mouse peritoneal inflammation. J Pharmacol Exp Ther 269 (1994) 917
26. Byrum R.S., Goulet J.L., Snouwaert J.N., Griffiths R.J., and Koller B.H. Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase-and leukotriene A4 hydrolase-deficient mice. J Immunol 163 (1999) 6810-6819
27. Bannenberg G., Moussignac R.L., Gronert K., et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 143 (2004) 43-52
28. Forrest M.J., Jose P.J., and Williams T.J. Kinetics of the generation and action of chemical mediators in zymosan-induced inflammation of the rabbit peritoneal cavity. Br J Pharmacol 89 (1986) 719-730
29. Kolaczkowska1 M., Barteczko1 B., Plytycz1 B., and Arnold E. Role of lymphocytes in the course of murine zymosan-induced Peritonitis. Inflamm Res 57 (2008) 272-278
30. Arita M., Bianchini F., Aliberti J., et al. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201 (2005) 713-722
31. Sun Y.P., Oh S.F., Uddin J., et al. Resolvin D1 and its aspirin-triggered 17R Epimer stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem 282 13 (2007) 9323-9334
32. Bakavoli M., Nikpour M., Rahimizadeh M., Saberi M.R., and Sadeghian H. Design and synthesis of pyrimido[4,5-b][1,4]benzothiazine derivatives, as potent 15-lipoxygenase inhibitors. Bioorg Med Chem 15 5 (2007) 2120-2126
33. Rao N.L., Dunford P.J., Xue X., et al. Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J Pharmacol Exp Ther 321 (2007) 1154-1160
34. 2 plays a key role in zymosan-induced mouse pleurisy. Pharmacol J Exp Ther 325 2 (2008) 601-609
35. Serhan C.N., Hamberg M., and Samuelsson B. Trihydroxytetraenes; a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem Biophys Res Commun 8 3 (1984) 43-49
36. Kühn H., Brash A.R., Wiesner R., and Alder L. Lipoxygenase catalyzed oxygenation of hydroxyl fatty acids to lipoxins. Adv Exp Med Biol 229 (1988) 39-49
37. Bild G.S., Ramadoss C.S., and Axelrod B. Multiple dioxygenation by lipoxygenase of lipids containing all-cis-1,4,7-octatriene moieties. Arch Biochem Biophys 184 1 (1977) 36-41
38. Griswold D.E., Webb E.F., and Hillegass L.M. Induction of plasma exudation and inflammatory cell infiltration by leukotriene C4 and leukotriene B4 in mouse peritonitis. Inflammation 15 4 (1991) 251-258
39. Vanderhoek J.Y., Bryant R.W., and Bailey J.M. Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. J Biol Chem 255 21 (1980) 10064-10066
40. Serhan C.N., and Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8 5 (2008) 349-361
41. Serhan C.N., Tankano T., Chiang N., Gronert K., and Clish C.B. Formation of endogenous "antiinflammatory" lipid mediators by transcellular biosynthesis. Lipoxins and aspirin-triggered lipoxins inhibit neutrophil recruitment and vascular permeability. Am J Respir Crit Care Med 161 2 (2000) 95-101
42. Serhan C.N. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell-cell interactions or a therapeutic opportunity?. Prostaglandins 53 2 (1997) 107-137
43. Serhan C.N., Hamberg M., Samuelsson B., and Lipoxins. novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 81 (1984) 5335-5339
44. Schwarz K., Borngräber S., Anton M., and Kuhn H. Probing the substrate alignment at the active site of 15-lipoxygenases by targeted substrate modification and site-directed mutagenesis. Evidence for an inverse substrate orientation. Biochemistry 37 44 (1998) 15327-15335
45. Lundy S.R., Dowling R.L., Stevens T.M., Kerr J.S., Mackin W.M., and Gans K.R. Kinetics of phospholipase A2, arachidonic acid, and eicosanoid appearance in mouse zymosan peritonitis. J Immunol 144 (1990) 2671-2677
46. Bierbaum T.J., Bouma S.R., and Huestis W.H. A mechanism of erythrocyte lysis by lysophosphatidylcholine. Biochim Biophys Acta 555 (1979) 102-110
47. Serhan C.N., and Chiang N. Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus. Br J Pharmacol 153 1 (2008) 200-215